Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
